Evidence map›Paper›PMID 40243730›Full record

ArticleInternational journal of molecular sciences2025

Assessment of Cardiovascular Risk in the PURE Poland Cohort Study Using the Systematic Coronary Risk Evaluation (SCORE) Scale and Galectin-3 Concentrations: A Cross-Sectional Study.

Adrian Martuszewski, Patrycja Paluszkiewicz, Katarzyna Połtyn-Zaradna, Agnieszka Kusnerż, Rafał Poręba, Andrzej Szuba, Paweł Gać, Katarzyna Zatońska

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Adrian MartuszewskiDepartment of Environmental Health, Occupational Medicine and Epidemiology, Wroclaw Medical University, Mikulicza-Radeckiego 7, 50-345 Wrocław, Poland.ORCID 0000-0002-3620-6380
Patrycja PaluszkiewiczDepartment of Neurology, Specialist Hospital in Walbrzych, Sokołowskiego 4, 58-309 Wałbrzych, Poland.ORCID 0000-0002-5701-9349
Katarzyna Połtyn-ZaradnaDepartment of Population Research and Prevention of Civilization Diseases, Wroclaw Medical University, Bujwida 44, 50-372 Wrocław, Poland.
Agnieszka KusnerżDepartment of Environmental Health, Occupational Medicine and Epidemiology, Wroclaw Medical University, Mikulicza-Radeckiego 7, 50-345 Wrocław, Poland.
Rafał PorębaDepartment of Biological Principles of Physical Activity, Wroclaw University of Health and Sport Sciences, 51-612 Wrocław, Poland.
Andrzej SzubaDepartment of Angiology and Internal Diseases, Wroclaw Medical University, Borowska 213, 50-556 Wrocław, Poland.
Paweł GaćDepartment of Environmental Health, Occupational Medicine and Epidemiology, Wroclaw Medical University, Mikulicza-Radeckiego 7, 50-345 Wrocław, Poland.ORCID 0000-0001-8366-0239
Katarzyna ZatońskaDepartment of Population Research and Prevention of Civilization Diseases, Wroclaw Medical University, Bujwida 44, 50-372 Wrocław, Poland.ORCID 0000-0002-3772-5588

Funding

Wroclaw Medical University SUBZ.E264.25.064 and SUBZ.E260.24.047
6 · The paper itself

Abstract

The SCORE (Systematic Coronary Risk Evaluation) scale is useful for cardiovascular disease (CVD) risk stratification. However, there is a new biomarker, namely, galectin-3 (gal-3), that offers additional predictive value. This cross-sectional study assessed the relationship between serum gal-3 concentrations and CVD risk based on the SCORE scale in a Polish cohort from the PURE study. A total of 259 participants with complete cholesterol, blood pressure (BP), and smoking data were included. Individuals with myocardial infarction, stroke, diabetes, or renal failure were excluded. Gal-3 concentrations were measured using ELISA, and statistical analyses examined associations with SCORE categories. The median gal-3 concentration was 221.32(161.64-360.00) ng/mL. Higher gal-3 concentrations were found in older individuals, smokers, and those with elevated BP(

Indexed as

Cardiovascular DiseasesGalectin 3AdultAgedBiomarkersBlood PressureBlood ProteinsCohort StudiesCross-Sectional StudiesFemaleGalectinsHeart Disease Risk FactorsHumansMaleMiddle AgedPolandBiomarkersBlood ProteinsGalectin 3GalectinsLGALS3 protein, humanbiomarkerscardiovascular diseasesgalectin-3 levelrisk assessmentSCORE scale

Identifiers

PMID40243730
PMCPMC11989118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.